You are here

Yescarta

Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas

Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas

MedCity News

Gilead Sciences

follicular lymphoma

marginal zone lymphoma

Flag link:

Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online

Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online

Fierce Pharma

Gilead Sciences

drug manufacturing

Flag link:

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

Fierce Pharma

Gilead Sciences

refractory large B-cell lymphoma

Flag link:

Celgene posts pivotal CAR-T data ahead of FDA filing

Celgene posts pivotal CAR-T data ahead of FDA filing

Fierce Biotech

Flag link:

Gilead third-quarter results in line, but Yescarta sales dip

Gilead third-quarter results in line, but Yescarta sales dip

Yahoo/Reuters

Gilead Sciences

Flag link:

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Yahoo/Reuters

Flag link:

Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Fierce Pharma

Gilead Sciences

Flag link:

Gilead highlights Yescarta survival data in ASCO update

Gilead highlights Yescarta survival data in ASCO update

Pharmaforum

Gilead Sciences

clinical trials

relapsed or refractory diffuse large B-cell lymphoma

Flag link:

Medicare would cover CAR-T cell therapies under new CMS proposal

Medicare would cover CAR-T cell therapies under new CMS proposal

Marketwatch

Gilead Sciences

Flag link:

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

Xconomy

Gilead Sciences

Flag link:

2 Sets of Disasters Biotech Will Pay For in 2019

2 Sets of Disasters Biotech Will Pay For in 2019

Yahoo/Motley Fool

Gilead Sciences

Spark Therapeutics

Flag link:

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

Fierce Pharma

Flag link:

NHS, Gilead reach agreement for Yescarta

NHS, Gilead reach agreement for Yescarta

BioCentury

Gilead Sciences

Flag link:

UK rejects Gilead's CAR-T cancer cell therapy as too expensive

UK rejects Gilead's CAR-T cancer cell therapy as too expensive

Reuters

Gilead Sciences

Flag link:

Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma

Kite Receives Positive Opinion from CHMP for Yescarta in Lymphoma

CP Wire

Gilead Sciences

B-cell lymphoma

Flag link:

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Could an old Amgen-developed RA drug make CAR-T treatments safer?

Fierce Biotech

cytokine release syndrome

Flag link:

Gilead finds new home in Europe for CAR-T manufacturing

Gilead finds new home in Europe for CAR-T manufacturing

Biopharma Dive

Gilead Sciences

drug manufacturing

Flag link:

New approval sets up CAR-T showdown for Gilead, Novartis

New approval sets up CAR-T showdown for Gilead, Novartis

Biopharma Dive

Gilead Sciences

Flag link:

Medicare sets outpatient rate for Yescarta reimbursement

Medicare sets outpatient rate for Yescarta reimbursement

Reuters

Gilead Sciences

Flag link:

5 Drugs That Are Critical for Gilead Sciences' Future

5 Drugs That Are Critical for Gilead Sciences' Future

Motley Fool

Gilead Sciences

Flag link:

Pages